dazukibart

Dazukibart is a humanized monoclonal antibody that acts as a potent and selective inhibitor of interferon beta (IFN-beta). It is being developed primarily for the treatment of idiopathic inflammatory myopathies, including dermatomyositis and polymyositis. Dazukibart works by binding to IFN-beta, thereby preventing its signaling through the IFN-alpha/beta receptor, which leads to reduced production of pro-inflammatory cytokines and modulation of immune responses. This mechanism targets the overactive type I interferon pathway implicated in muscle inflammation and weakness characteristic of these diseases. The drug has shown efficacy in reducing disease activity in clinical trials for dermatomyositis and polymyositis, with additional studies ongoing for cutaneous lupus erythematosus and systemic lupus erythematosus[1][3][5][7][8].

Other names

Immunoglobulin G1 [236-alanine,237-alanine,239-alanine,de-C-terminal-lysine], anti-(human interferon β) (human-Mus musculus monoclonal PF-06823859 γ1-chain), disulfide with human-Mus musculus monoclonal PF-06823859 κ-chain, dimerMab humanized (igg1) anti p01574 (ifnb_human) (pf06823859)recombinant humanized monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1kappa) directed against human soluble cytokine interferon beta[7]